Pacira Pharm Inc (PCRX) Stock Price, Quote & News

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 813 553 6680

Website: www.pacira.com

Address:

5401 West Kennedy Boulevard, Suite 890, Tampa, United States

GoldKing23 Nov. 11 at 9:41 PM

$PCRX sounding very similar to when Sanofi acquired Genzyme in a $20.1 billion deal announced in February 2011 following about 7 months of public discussions and negotiations after sale rumors surfaced in mid-2010. The acquisition paid $74 per share plus contingent value rights (CVRs) to Genzyme shareholders. https://seekingalpha.com/news/4519996-pacira-biosciences-gains-as-investor-calls-for-full-sales-process?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news

0 · Reply

JarvisFlow Nov. 7 at 4:52 PM

Truist Securities has adjusted their stance on Pacira BioSciences ( $PCRX ), setting the rating to Buy with a target price of 30 → 28.

0 · Reply

Maestro60 Nov. 7 at 3:00 PM

$PCRX +8% good day after earnings

0 · Reply

d_risk Nov. 7 at 12:14 AM

$PCRX - Pacira BioSciences Inc. Common Stock - 10Q - Updated Risk Factors PCRX warns its pMVL product patents cover only specific formulations and uses, not the active ingredients, leaving market share vulnerable to competitors with alternative delivery technologies. #Pharmaceuticals #DrugDeliveryTechnology #MarketCompetition #PatentRisk 🟢 Added 🟠 Removed https://d-risk.ai/PCRX/10-Q/2025-11-06

0 · Reply

A_Train1 Nov. 6 at 11:57 PM

$PCRX terrible - just terrible

0 · Reply

DonCorleone77 Nov. 6 at 9:37 PM

$PCRX Pacira reports Q3 EPS 70c, consensus 65c -- Q3 revenue $179.52M, consensus $182.33M. -- Cuts FY25 revenue view to $725M-$735M from $730M-$750M, consensus $737.15M. -- Raises FY25 gross margin view to 80%-82% from 78%-80%.

0 · Reply

Maestro60 Nov. 6 at 2:50 PM

$PCRX 👀

0 · Reply

ZacksResearch Nov. 3 at 2:33 PM

4 biotech stocks primed for a surprise — are you ready? 🔍 💊 $ZYME: +2.22% Earnings ESP, Zacks Rank #1, reporting Nov. 6 🧬 $NKTR: +18.72% Earnings ESP, Zacks Rank #2, reporting Nov. 6 💉 $ANIP: +10.55% Earnings ESP, Zacks Rank #2, reporting Nov. 7 🔬 $PCRX: +2.68% Earnings ESP, Zacks Rank #3, reporting Nov. 6 Discover their potential for earnings surprises here 👉 https://www.zacks.com/stock/news/2783287/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates?cid=sm-stocktwits-2-2783287-body-19028&ADID=SYND_STOCKTWITS_TWEET_2_2783287_BODY_19028

1 · Reply

ZacksResearch Nov. 3 at 1:33 PM

Biotech breakout ahead? 🔬 $ZYME, $NKTR, $ANIP, and $PCRX are all positioned for potential Q3 earnings surprises, with sector momentum pointing to upside. Full earnings preview here 👉 https://www.zacks.com/stock/news/2783287/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates?cid=sm-stocktwits-2-2783287-teaser-19027&ADID=SYND_STOCKTWITS_TWEET_2_2783287_TEASER_19027

0 · Reply

A_Train1 Oct. 27 at 11:45 AM

$PCRX what does today bring?

1 · Reply

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Nov 10, 2025, 8:09 PM EST - 4 days ago

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Nov 7, 2025, 6:16 AM EST - 7 days ago

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 8 days ago

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Nov 5, 2025, 8:00 AM EST - 9 days ago

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Nov 4, 2025, 7:00 AM EST - 10 days ago

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Oct 30, 2025, 8:00 AM EDT - 15 days ago

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Oct 27, 2025, 8:00 AM EDT - 18 days ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Oct 23, 2025, 8:00 AM EDT - 22 days ago

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Oct 21, 2025, 8:30 AM EDT - 24 days ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

Oct 20, 2025, 4:01 PM EDT - 25 days ago

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

Oct 3, 2025, 8:00 AM EDT - 6 weeks ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 6, 2025, 2:42 AM EDT - 3 months ago

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:00 PM EDT - 3 months ago

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Jul 16, 2025, 8:40 AM EDT - 4 months ago

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

Jun 17, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 5 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Jun 1, 2025, 10:00 AM EDT - 5 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

May 20, 2025, 10:00 AM EDT - 6 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

May 13, 2025, 10:35 AM EDT - 6 months ago

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

May 13, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

May 11, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

May 8, 2025, 10:31 PM EDT - 6 months ago

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:00 PM EDT - 6 months ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 8, 2025, 10:00 AM EDT - 6 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 6, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

May 4, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

May 2, 2025, 8:00 AM EDT - 7 months ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025, 10:00 AM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Apr 24, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

Apr 22, 2025, 4:01 PM EDT - 7 months ago

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

Apr 22, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out

Apr 21, 2025, 8:15 AM EDT - 7 months ago

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Apr 17, 2025, 5:00 PM EDT - 7 months ago

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Apr 9, 2025, 10:03 AM EDT - 7 months ago

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

GoldKing23 Nov. 11 at 9:41 PM

0 · Reply

JarvisFlow Nov. 7 at 4:52 PM

Truist Securities has adjusted their stance on Pacira BioSciences ( $PCRX ), setting the rating to Buy with a target price of 30 → 28.

0 · Reply

Maestro60 Nov. 7 at 3:00 PM

$PCRX +8% good day after earnings

0 · Reply

d_risk Nov. 7 at 12:14 AM

0 · Reply

A_Train1 Nov. 6 at 11:57 PM

$PCRX terrible - just terrible

0 · Reply

DonCorleone77 Nov. 6 at 9:37 PM

0 · Reply

Maestro60 Nov. 6 at 2:50 PM

$PCRX 👀

0 · Reply

ZacksResearch Nov. 3 at 2:33 PM

1 · Reply

ZacksResearch Nov. 3 at 1:33 PM

0 · Reply

A_Train1 Oct. 27 at 11:45 AM

$PCRX what does today bring?

1 · Reply

Arcides Oct. 21 at 2:25 PM

$PCRX getting broke....

1 · Reply

Thestocktraderhubzee Oct. 21 at 10:23 AM

WATCHLIST OCT 21 2025 $LMT Lockheed Martin Says It Has Been Developing Moon Lander Plans That Could Fulfill Nasa's Need For Alternative To SpaceX's Starship $PCRX Pacira Biosciences To Present New Data From Phase 1 Clinical Trial Evaluating PCRX-201, Gene Therapy Candidate For Osteoarthritis Of Knee, At ACR Convergence 2025 Meeting $LPTH LightPath Technologies shares are trading higher after the company announced it received a $4.8 million purchase order for infrared camera systems. $IDYA BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target $WD Walker & Dunlop Secures $40.5M Financing For 137-Unit Affordable Senior Housing Project "The Highlands" In Hyattsville, Maryland

0 · Reply

A_Train1 Oct. 13 at 2:13 PM

$PCRX ugly 1 month chart

1 · Reply

A_Train1 Oct. 9 at 5:11 PM

$PCRX wow

0 · Reply

A_Train1 Oct. 6 at 3:07 PM

$PCRX this thing is hurting

0 · Reply

VolatiliGuy Oct. 5 at 4:41 PM

$PCRX Pharmaceutical technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.

0 · Reply

GoldKing23 Oct. 3 at 7:28 PM

$PCRX positive earnings loading...

1 · Reply

A_Train1 Sep. 29 at 1:41 PM

$PCRX any thoughts on the Monday dip??? Anyone? Bueller?

0 · Reply

A_Train1 Sep. 29 at 1:21 PM

any thoughts on the late Friday dip? Is anybody even here? This feels like a dead board.$PCRX

0 · Reply

jacksonjohn750 Sep. 25 at 10:26 AM

$PCRX you need to buy Heron and show them how to sell it

0 · Reply

A_Train1 Sep. 18 at 12:33 PM

$PCRX does anyone think there’s any chance that J & J would acquire this company?

1 · Reply

Doozio Sep. 13 at 5:12 PM

$PCRX 🍔s during 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	1.02B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	N/A
PE Ratio	11.75
Forward PE	12.22
Profit Margin	-14.20%
Debt to Equity Ratio	0.52

Volume	523,500
Avg Vol	614,898
Day's Range	N/A - N/A
Shares Out	43.02M
Stochastic %K	87%
Beta	0.36
Analysts	Sell
Price Target	$28.60